Results 1 to 10 of about 4,835,110 (353)

Current Status and Future Prospects for Esophageal Cancer

Cancers, 2023
Simple Summary Over 500,000 individuals died due to esophageal cancer (EC) worldwide in 2020. More than four decades of etiological research have predominantly focused on the esophageal squamous cell carcinoma (ESCC) subtype, which accounts for 80% of EC
Mahdi Sheikh, G. Roshandel, V. McCormack, R. Malekzadeh   +3 more
semanticscholar   +1 more source

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

New England Journal of Medicine, 2021
BACKGROUND No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.
R. Kelly, J. Ajani, J. Kużdżał, T. Zander, E. Van Cutsem, G. Piessen, G. Mendez, J. Feliciano, S. Motoyama, A. Lièvre, H. Uronis, E. Elimova, C. Grootscholten, K. Geboes, S. Zafar, S. Snow, A. Ko, K. Feeney, M. Schenker, Piotr Kocoń, Jenny Zhang, Lili Zhu, M. Lei, Prianka Singh, K. Kondo, J. Cleary, M. Moehler   +26 more
semanticscholar   +1 more source

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Journal of Clinical Oncology, 2021
PURPOSE Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer.
B. Eyck, J. V. van Lanschot, M. Hulshof, B. J. van der Wilk, J. Shapiro, P. van Hagen, M. I. van Berge Henegouwen, B. Wijnhoven, H. V. van Laarhoven, G. Nieuwenhuijzen, G. Hospers, J. Bonenkamp, M. Cuesta, R. Blaisse, O. Busch, G. Creemers, C. Punt, J. Plukker, H. Verheul, E. S. Spillenaar Bilgen, M. V. D. van der Sangen, T. Rozema, F. T. ten Kate, J. Beukema, A. Piet, C. M. Van rij, J. Reinders, H. Tilanus, E. Steyerberg, A. van der Gaast   +29 more
semanticscholar   +1 more source

Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040

Thoracic Cancer, 2022
Esophageal cancer is a familiar malignancy with high incidence and mortality, and the overall prognosis is poor. The numbers of cases of and deaths from esophageal cancer have risen rapidly in recent decades. It is one of the most malignant cancers, with
Chunquan Liu, Yunlei Ma, Qi Qin, Pei‐Hao Wang, Yi Luo, Peng‐Fei Xu, Yong Cui   +6 more
semanticscholar   +1 more source

Esophageal cancer in China: Practice and research in the new era

International Journal of Cancer, 2022
China, as the one of the largest developing countries in the world and with about one‐fifth of the global population, is bearing an increasing burden on health from cancer.
Hongcheng Zhu, Xiao Ma, T. Ye, Honggang Wang, Zezhou Wang, Qi Liu, K. Zhao   +6 more
semanticscholar   +1 more source

CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p

Molecular Cancer, 2022
Rationale Circular RNAs (circRNAs) have been demonstrated to contribute to esophageal cancer progression. CircBCAR3 (hsa_circ_0007624) is predicted to be differentially expressed in esophageal cancer by bioinformatics analysis.
Y. Xi, Yaxing Shen, Dong-ning Wu, Jingtao Zhang, Chengbin Lin, Lijie Wang, Chaoqun Yu, Bentong Yu, W. Shen   +8 more
semanticscholar   +1 more source

Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

Cancer Metastasis Review, 2022
Esophageal cancer (EC) is frequently considered a lethal malignancy and is often identified at a later stage. It is one of the major causes of cancer-related deaths globally. The conventional treatment methods like chemotherapy, radiotherapy, and surgery
Tarang Sharma, Ashna Gupta, Ravi D. Chauhan, A. Bhat, Sabah Nisar, Sheema Hashem, Sabah Akhtar, Aamir Ahmad, Mohammad Haris, Mayank Singh, S. Uddin   +10 more
semanticscholar   +1 more source

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Journal of Clinical Oncology, 2020
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced ...
T. Kojima, Manish A. Shah, K. Muro, E. François, A. Adenis, Chih-Hung Hsu, T. Doi, T. Moriwaki, Sung-Bae Kim, Se-Hoon Lee, J. Bennouna, Ken Kato, L. Shen, P. Enzinger, S. Qin, P. Ferreira, Jia Chen, G. Girotto, C. de la Fouchardière, H. Sénellart, R. Al-Rajabi, F. Lordick, Rui-xue Wang, S. Suryawanshi, P. Bhagia, S. Kang, J. Metges   +26 more
semanticscholar   +1 more source

Global and national trends in the age‐specific sex ratio of esophageal cancer and gastric cancer by subtype

International Journal of Cancer, 2022
A male predominance was observed in esophageal and gastric cancers, though present limited data has revealed variations by age. We aim to investigate the global age‐specific sex differences in esophageal squamous cell carcinoma (ESCC), esophageal ...
Shaoming Wang, R. Zheng, M. Arnold, C. Abnet, H. Zeng, Siwei Zhang, Ru Chen, K. Sun, Li Li, Lan An, F. Bray, Wenqiang Wei, Jie He   +12 more
semanticscholar   +1 more source

Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries

Cancers, 2021
Simple Summary Esophageal cancer is the seventh most common cancer globally. Preventive measures and clinical management differ based on histologic subtype.
Junjie Huang, Anastasios Koulaouzidis, W. Marlicz, Veeleah Lok, Cedric Chu, C. Ngai, Lin Zhang, Ping Chen, Shanjuan Wang, Jinqiu Yuan, X. Lao, Shelly L. A. Tse, Wanghong Xu, Zhi‐Jie Zheng, Shaohua Xie, M. Wong   +15 more
semanticscholar   +1 more source